A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non-Small Cell Lung Cancer

Purpose: Mutation of the Kirsten ras sarcoma viral oncogene homolog (KRAS) and loss of p53 function are commonly seen in patients with non-small cell lung cancer (NSCLC). Combining therapeutics targeting these tumor-defensive pathways with cisplatin in a single-nanoparticle platform are rarely devel...

Full description

Bibliographic Details
Main Authors: Gu, Li (Author), Deng, Zhou J. (Author), Roy, Sweta (Author), Hammond, Paula T (Author)
Other Authors: Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: American Association for Cancer Research (AACR), 2021-04-27T19:46:05Z.
Subjects:
Online Access:Get fulltext

Similar Items